FDA Grants Priority Review to Ivosidenib for IDH1+ Relapsed/Refractory MDS

The FDA has granted priority review to the supplemental new drug application seeking the approval of ivosidenib for the treatment of patients with IDH1-mutated, relapsed/refractory myelodysplastic syndrome.

Related Keywords

Germany ,Susan Pandya ,European Hematology Association Congress ,European Hematology Association ,Cancer Metabolism Global Development Oncology Immuno ,York Heart Association ,Cancer Metabolism Global Development Oncology ,New York Heart Association ,Hematology Association ,Hematology Association Congress ,Ivosidenib ,Patients With Idh1 Mutated ,Elapsed Refractory Myelodysplastic Syndrome ,Nct02074839 ,D ,Servier ,